Amgen's (AMGN) stock has been experiencing a steady increase due to the promising results of its experimental obesity drug. The bio-tech giant surpassed its earnings and revenue estimates in the Q1 2024 and instilled confidence in investors. Moreover, Amgen reported strong growth and strategic advances during its Q1 2024 earnings call. Despite occasional market fluctuations, the stock often rallied, notably after key updates on the weight-loss drug. Goldman Sachs and William Blair have given optimistic comments and upgrades. Yet, there are times when the stock saw significant drops compared to the general market.
Amgen AMGN News Analytics from Thu, 09 Nov 2023 06:15:22 GMT to Wed, 08 May 2024 16:01:15 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 0
